Oculis (OCS) Fireside Chat summary

Introduction and agenda

• Panelists discussed multiple drug candidates in pivotal clinical development for retinal disorders, focusing on dry AMD, GA, retinitis pigmentosa, Stargardt disease, and DME.

Background and experience of the speaker

• Dr. Breazzano transitioned to the University of Rochester, leading a retina surgery and disease fellowship.

Current industry trends

• Advances in anti-complement and anti-VEGF therapies are shaping the landscape for retinal disease treatment.

• Gene therapy is making significant progress, especially for inherited retinal diseases like RPE65-related conditions.

• Non-invasive delivery methods, such as topical eye drops and oral therapies, are gaining traction.